Aflac stock (US0010551028): Moody's assigns A3 rating to senior notes

Aflac Incorporated saw Moody's Investors Service assign an A3 rating to its senior unsecured notes on May 11, 2026, with a stable outlook. This rating action reflects the company's solid position in supplemental health insurance, despite a recent Q4 EPS miss of $1.75 versus $1.80 expected, as reported in MarketBeat as of 05/12/2026. Separately, director Joseph L. Moskowitz sold 600 shares at $113.73, per GuruFocus as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Aflac: core business model

Aflac provides supplemental insurance products that cover out-of-pocket expenses not paid by major medical insurance, such as cancer, accident, and life policies. Operating primarily in the US and Japan, the company targets employers and associations for group sales. Shares traded at $115.44 on May 12, 2026, on NYSE, according to MarketBeat as of 05/12/2026.

Main revenue and product drivers for Aflac

Revenue stems from premiums in supplemental health lines, with Japan contributing significantly alongside US growth in voluntary benefits. Recent Q4 results showed revenue beat but EPS shortfall for the period ended December 31, 2025, published in early 2026 filings. Institutional moves included Securian Asset Management reducing its stake by 44.8% to 12,826 shares worth $1.41 million in Q4 2025, per MarketBeat as of 05/12/2026.

Industry trends and competitive position

The supplemental insurance sector benefits from rising US healthcare costs, positioning Aflac strongly against peers like Colonial Life. Moody's A3 rating on May 11, 2026, underscores financial stability, per Moody's as of 05/11/2026. Aflac's US exposure makes it relevant for American investors tracking insurance amid economic shifts.

Conclusion

Aflac's recent Moody's A3 rating and ongoing institutional activity highlight its steady role in supplemental insurance. While insider sales and an EPS miss warrant monitoring, the stable outlook supports its US market presence. Investors should review latest filings for full context on performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.